Pivotal trials (e.g., KEYNOTE-024 [9], CheckMate 026 [10]) established anti-PD-1 agents ± chemotherapy as first-line therapy for PD-L1-high or driver-negative NSCLC, elevating 5-year survival to 23–31%. This evidence concerns the gene CD274 and non-small cell lung carcinoma.